Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 12/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 12/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 12/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 12/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 12/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 12/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24599434 | 0.86 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL24599356 | 0.81 | ALDH1A1 (0.36) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL24624656 | 0.81 | PSEN1 (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL24599388 | 0.76 | ALDH1A1 (0.48) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL24599484 | 0.72 | ALDH1A1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL15939461 | 0.67 | ALDH1A1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL24908432 | 0.64 | KDM4E (0.36) | MAPT | |
| SCHEMBL24908490 | 0.62 | GPR84 (0.38) | MAPT | |
| SCHEMBL25452696 | 0.62 | GPR84 (0.38) | MAPT | |
| SCHEMBL22532336 | 0.62 | TSHR (0.41) | SMN1; SMN2MAPTHTTTSHRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227446-A9 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20220213096-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NANJING ZHENGXIANG PHARMACEUTICALS CO LTD (CN) | 2022-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227446-A9 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PI4KB, PI4KA, PIK3CD | PSEN1 3482/4885PSEN2 3211/4885APH1B 1613/4885 |
| US-20220213096-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PI4KB, PI4KA, PIK3CD | PSEN1 3482/4885PSEN2 3211/4885APH1B 1613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.